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Abstract: Stroke is a leading cause of morbidity and mortality in the United States. Despite intensive research into the 
development of treatments that lessen the severity of cerebrovascular injury, no major therapies exist. Though the poten-
tial use of adenosine as a neuroprotective agent in the context of stroke has long been realized, there are currently no 
adenosine-based therapies for the treatment of cerebral ischemia and reperfusion. One of the major obstacles to develop-
ing adenosine-based therapies for the treatment of stroke is the prevalence of functional adenosine receptors outside the 
central nervous system. The activities of peripheral immune and vascular endothelial cells are particularly vulnerable to 
modulation via adenosine receptors. Many of the pathophysiological processes in stroke are a direct result of peripheral 
immune infiltration into the brain. Ischemic preconditioning, which can be induced by a number of stimuli, has emerged 
as a promising area of focus in the development of stroke therapeutics. Reprogramming of the brain and immune re-
sponses to adenosine signaling may be an underlying principle of tolerance to cerebral ischemia. Insight into the role of 
adenosine in various preconditioning paradigms may lead to new uses for adenosine as both an acute and prophylactic 
neuroprotectant. 
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INTRODUCTION  
  Ischemia occurs when blood flow to an organ is inhib-
ited, resulting in a lack of delivery of oxygen and nutrients, 
and  a  decreased  clearance  of  potentially  toxic  metabolic 
waste products. The brain is selectively vulnerable to ische-
mia, as it does not store glycogen but instead relies on glu-
cose from the blood. The major strategies used to treat stroke 
focus on the re-establishment of blood flow to affected tis-
sue. This process of reperfusion has the potential to increase 
damage to ischemic tissue by generating oxygen-derived free 
radicals. Thus, it is essential to develop therapies that target 
both ischemic and reperfusion-related injury in stroke. 
  Cerebral ischemia is one of the leading causes of morbid-
ity and mortality in the United States. Each year, more than 
780,000 individuals suffer from a stroke [94], 87% of which 
are ischemic [53]. In addition to stroke, brain ischemia and 
reperfusion (IR) injury can be caused by cardiac arrest. In 
fact, brain injury affects at least 1/3 of individuals who sur-
vive  a  heart  attack  [93].  Development  of  novel  drugs  for 
cerebral  ischemic  injury  is  a  necessity.  Many  instances  of 
stroke are predictable; as many as 0.7% of all surgery pa-
tients  will  suffer  from  surgery-associated  brain  ischemia 
[55], while 10% of patients undergoing cardiac or vascular 
surgeries will suffer from a frank stroke during or after sur-
gery [11, 15, 40, 55, 69, 76]. Prophylactic neuroprotection 
has emerged  as  a promising field of study. Adenosine, an 
endogenous purine nucleoside that modulates many physio-
logical processes and its receptors have shown great promise  
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as therapeutic targets in the reduction of damage following 
experimental stroke. In addition to their value as post-stroke 
treatments  that  reduce  the  extent  of  stroke  damage,  these 
compounds are prime candidates for prophylactic neuropro-
tection. 
BRIEF  HISTORY  OF  ADENOSINE-BASED  THERA-
PIES IN STROKE 
  For  some  time  adenosine  and  its  receptors  have  been 
viewed as potential therapeutic targets for the treatment of 
stroke. In practice, however,  adenosine-based therapies for 
the treatment of stroke have proven complex in their imple-
mentation [107]. Difficulties stem from the widespread dis-
tribution of adenosine receptors within the  central nervous 
system (CNS) and throughout the body. For this reason, even 
direct  targeting  of  specific  adenosine  receptors  leads  to 
widespread  off-target  effects.  Further  complications  in  de-
veloping robust adenosine-based therapeutics include imper-
fect targeting of specific receptor subtypes by agonists and 
antagonists. Finally, stroke is comprised of a complex set of 
pathophysiological  processes  that  are  influenced  differen-
tially by adenosine spatially and temporally. 
BASIC PHYSIOLOGY OF ADENOSINE AND ITS RE-
CEPTORS 
  The adenosine receptor family consists of four members: 
A1, A2A, A2B and A3 receptors. Adenosine receptors consist 
of seven transmembrane spanning regions, and are coupled 
to G proteins, which activate a number of intracellular sig-
naling  pathways  [45].  Adenosine  receptors  are  broadly 
grouped  into  two  categories:  A1  and  A3  receptors,  which 
couple to inhibitory G proteins, and A2A and A2B receptors, 
which couple to stimulatory G proteins. However, adenosine 
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proteins and transduction systems according to their degree 
of activation and their particular cellular or subcellular loca-
tion [24].  
  Extracellular adenosine levels are low under normal con-
ditions, but increase substantially in response to metabolic 
stress  [10,  29,  45].  Extracellular  adenosine  levels  are  in-
creased under stress via several mechanisms: 1) inhibition of 
equilibrative nucleoside transporters, 2) increased release of 
ATP from cells and stimulation of extracellular breakdown 
of ATP by ectonucleotidases, and 3) inhibition of intracellu-
lar adenosine removal [10, 29]. Rapid elevations in adeno-
sine occur following ischemia in vitro such that within 10 
minutes of ischemia adenosine levels in hippocampal slices 
are increased by more than 20µM [82]. In vivo studies also 
show increases in adenosine in the CNS with cerebral ische-
mia [61]. For a more thorough discussion of the source of 
adenosine in ischemia and in epilepsy, please see Frenguelli 
& Dale, this issue. Interestingly, increased levels of adeno-
sine during stroke are not limited to the CNS, as adenosine 
levels in serum have also been shown to increase following 
transient ischemic attack (TIA) and stroke in humans [62]. 
THE EFFECTS OF ADENOSINE RELEASE ON THE 
CNS DURING STROKE 
  Adenosine is a potent endogenous neuromodulator with 
known neuroprotective properties [23, 37, 91]. Administra-
tion of adenosine to the brain at the time of stroke amelio-
rates  damage  [57].  Further,  transgenic  overexpression  of 
adenosine kinase, the primary negative enzymatic regulator 
of adenosine, leads to increased vulnerability to ischemic cell 
death, presumably due to decreased levels of adenosine in 
the  CNS  [85].  In  practice,  however,  the  clinical  use  of 
adenosine as a neuroprotectant during stroke has been un-
successful. Adenosine is an imperfect neuroprotectant, as it 
can  provide  benefit  in  some  cases  and  exacerbate  tissue 
damage in others [23, 84]. Adenosine receptors are distrib-
uted throughout the body, and play a prominent role in car-
diac and renal system function. When administered intrave-
nously, adenosine at bolus doses of 6-12mg is used to treat 
patients  with  paroxysmal  supraventricular  tachycardia  to 
restore normal sinus rhythm by slowing conduction through 
the A-V node in the heart [32]. At higher doses, adenosine 
causes decreased blood pressure by decreasing vascular re-
sistance. Adenosine is also a respiratory stimulant, and intra-
venous  administration  can  increase  ventilation  and  reduce 
arterial PCO2 causing respiratory alkalosis. Decreased blood 
flow  and  respiration  compound  cerebral  ischemic  injury, 
superseding the potential neuroprotective properties of sys-
temically administered adenosine.  
  Targeted delivery of adenosine to the CNS in a controlled 
manner has also proven problematic. Adenosine has a very 
short half-life in human plasma (<5 seconds), and low blood 
brain  barrier  permeability  [81].  Molecules  with  greater 
plasma stability have been tested such as adenosine analogs, 
receptor-specific  agonists  and  antagonists,  and  enzymatic 
regulators  of  adenosine.  Pretreatment  with  the  unspecified 
adenosine agonist NECA (adenosine-5prime-N-ethylcarbox-
amide)  protects  human  astrocytoma  cells  from  apoptosis 
under hypoxic conditions in vitro [8]. Success has also been 
reported with adenosine agonists in rodent models of cere-
bral  ischemia.  Systemic  administration  of  the  adenosine 
kinase inhibitor GP683 at a moderate, but not high or low 
dose, to rats within 270 minutes of onset of surgical ischemia 
significantly reduces cerebral damage [104].  
  Unfortunately, the optimal window of administration for 
adenosine-modulating drugs has been difficult to determine. 
This is a common problem encountered by many potential 
stroke therapeutics that show promise in animal models, as 
accurate determination of the time of stroke onset is difficult 
in human patients. Stroke patients routinely face delays in 
access to  clinical  care, often due to a failure  to recognize 
stroke symptoms. The mean hospital arrival time for patients 
suffering  from  stroke  is  approximately  11  hours  after  the 
onset of vessel obstruction [4]. Once patients have been ad-
mitted to the hospital, more time may elapse before accurate 
diagnosis and treatment begins. Thus, stroke drugs with long 
time windows of efficacy are most desirable. In the case of 
adenosine, there is the added complication of a diverse dis-
tribution of adenosine receptors in the brain, whose actions 
can be opposing, either spatial or temporally. While admini-
stration of a specific adenosine receptor agonist early on may 
be  protective,  administration  of  the  same  drug  late  in  the 
course of stroke may exacerbate ischemic damage.  
  Direct  administration of adenosine-modulating drugs to 
the CNS is used in animal models to dissect the systemic and 
CNS effects of adenosine in stroke. These targeted experi-
mental therapies have shown efficacy in reducing ischemic 
damage in small animal models of stroke. Intracerebral ven-
tricular (ICV) administration of the selective A3R agonist Cl-
IB-MECA  (2-chloro-N6-(3-iodobenzyl)  adenosine-5'-N-
methylcarboxamide)  decreases  infarct  volume  in  a  mouse 
model of transient ischemia [18]. Clinically, ICV administra-
tion  of  drugs  is  impractical  and  the  uncertainty  about  the 
diverse temporal effects of adenosine receptor activation and 
blockade  remains  problematic.  While  animal  experiments 
using  ICV  administration  might  not  translate  directly  into 
clinical therapies, they provide insight into the local temporal 
effects of adenosine on the CNS. The specific functions of 
the adenosine receptors in the CNS in stroke have been fur-
ther illuminated by the development of increasingly selective 
adenosine receptor agonists and antagonists and the creation 
of  mice  with  targeted  deletions  in  the  adenosine  receptor 
system (Table 1). 
A1R Effects in the CNS 
  In the brain, the A1 subgroup is the most abundant and 
widespread  of  the  adenosine  receptors  [24].  A1  receptors 
have the highest  affinity for adenosine of all  the subtypes 
[29]. Under basal conditions, adenosine likely acts primarily 
via  this  receptor  subtype.  Based  on  immunohistochemical 
studies, A1 receptor expression has been shown to be high in 
the hippocampus,  cerebral  cortex, basal ganglia,  and some 
thalamic nuclei in humans and a variety of animals. A1 re-
ceptor expression is highest in neurons, but the receptor is 
also present on astrocytes, microglia, and oligodendrocytes 
[24]. A1 receptors are a central focus in the study of the neu-
roprotective  role  of  adenosine  in  stroke  due  to  their  high 
concentration and affinity for adenosine, known coupling to 
inhibitory G proteins and the large number of selective ago-
nists and antagonists available for use.  Adenosine and Stroke  Current Neuropharmacology, 2009, Vol. 7, No. 3    219 
  Activation of A1 receptors is generally considered protec-
tive in the context of noxious stimuli. The brain uses vast 
amounts of ATP generated by oxidative phosphorylation to 
maintain control of K
+ and Na
+ gradients in neurons. Func-
tion of the Na
+/K
+ ATPase is disrupted during ischemia be-
cause mitochondria are unable to make ATP when glucose 
and oxygen levels are low. Altered Na
+/K
+ ATPase activity 
leads  to  depolarization  of  the  neuronal  plasma  membrane 
and subsequent release of excitatory neurotransmitters. As a 
result,  calcium-permeable  NMDA  channels  open  causing 
calcium-meditated cell death. For a more complete review of 
excitotoxic cell death in stroke, please see Doyle K. P. et al., 
2008 [28]. A1 receptors are linked to inhibitory G proteins, 
which inhibit adenylyl cyclase, activate inward rectifying K
+ 
channels, inhibit Ca
2+ channels, and activate phospholipase 
C [10]. This has the cumulative effect of decreasing neuronal 
excitability. Activation of A1 receptors also leads to feedback 
inhibition of release of presynaptic excitatory neurotransmit-
ters,  such  as  glutamate.  Stimulation  of  A1  receptors  can 
therefore lead to prevention of excitotoxic cell death under 
ischemic conditions. 
  In  practice,  A1  receptor  activation  has  been  shown  to 
produce conflicting effects in both in vivo and in vitro mod-
els of cerebral ischemia. As neurons in the CA1 region of the 
hippocampus  are  particularly  susceptible  to  hypoxic  cell 
death, this region is often used as an indicator of tissue dam-
age in both in vitro and in vivo models of ischemia. In hippo-
campal slice preparations recovery from hypoxia, as meas-
ured by recovery of field EPSP (fEPSP) in the CA1 region, 
was  attenuated  by  the  application  of  the  A1R  antagonist 
DPCPX  (1,3-dipropyl-8-cyclopentylxanthine)  [97].  This 
result would suggest that antagonists of A1R have a detri-
mental effect in hypoxia, at least at the neuronal level. How-
ever,  application  of  the  A1R  antagonist  8-CPT  (8-cyclo-
pentyl  theophylline)  to  hippocampal  slices  at  the  time  of 
insult does not exacerbate hypoxia induced cell death in the 
CA1 region of hippocampus [78]. Hippocampal slices from 
A1R  knockout  mice  subjected  to  hypoxia  show  a  small, 
though  not  statistically  significant  decrease  in  damage  to 
neurons in the CA1 region [78]. A1R knockout mice, when 
exposed  to  global  ischemia,  show  no  increased  neuronal 
damage in the CA1 region of the hippocampus, the cortex, or 
the  striatum  as  compared  to  wildtype  controls  [78].  Mice 
treated  with  8-CPT  at  the  time  of  global  ischemia  have  a 
significant increase in cell death in the CA1 region, the cor-
tex and the striatum when compared to control-treated ani-
mals. Taken together, these results suggest that the protective 
effects of A1R activation are temporally regulated. Perhaps 
acute  stimulation  via A 1  receptors  provides  protection  by 
decreasing  synaptic  transmission,  but  during  recovery 
ischemia-induced  down-regulation  of  A1  receptors  may  be 
beneficial. 
A2AR Effects in the CNS 
  A2A receptors are also distributed widely throughout the 
brain. However, they are expressed at lower density in most 
regions than A1 receptors [24]. The highest density of A2A 
receptors can be found in the striatum [29]. The affinity of 
A2A receptors for adenosine is also relatively high. The ad-
vent of more selective A2A receptor agonists and antagonists, 
and the generation of A2A knockout mice, has revealed an 
important role of A2A receptors as mediators of neuroprotec-
tion in stroke. Because they are coupled to excitatory G pro-
teins, it would seem that stimulation of A2A receptors would 
exacerbate  ischemic  damage.  Paradoxically  when  applied 
centrally, A2A receptor antagonists afford protection in sev-
eral in vivo models of ischemic injury [38, 70, 72, 83, 108]. 
Further, A2A receptor knockout animals show a significant 
decrease in damage following focal cerebral ischemia [20]. 
The location of A2A receptors in the brain may also influence 
ischemic injury. In a model of permanent focal ischemia, a 
decrease in A2A receptor ligand affinity and an increase in 
receptor  expression  were  seen  in  the  striatum,  but  not  the 
cortex [105]. Stroke can occur in diverse regions of the brain 
depending on the specific vessels involved. It may be possi-
Table 1.  Effects of Adenosine on Cerebral Ischemia: Studies with Transgenic Animals 
Target  Manipulation  Model  Effect  Reference 
Adenosine 
kinase 
Overexpression in brain  tMCAO
a  3-fold increase in infarct volume vs. wildtype controls
b  [85] 
A1R  Global Knockout  Global Ischemia  No change in percentage dead neurons vs. wildtype 
controls 
[78] 
A2AR  Global Knockout  tMCAO  Reduction in infarct volume vs. wildtype controls  [20] 
A2AR  Bone Marrow Chimera   tMCAO  WT BMDCs→KO: ~20% decrease in infarct volume, 
not statistically significant
c 
KO BMDCs→WT: ~30% reduction in infarct volume, 
improved neurological outcome 
KO BMDCs→KO: ~60% decrease in infarct volume 
[117] 
A3R  Global Knockout  tMCA ligation  Increased infarct volume vs. wildtype controls  [18] 
a tMCAO: transient middle cerebral artery occlusion 
b MCAO given for 15 minutes.  60 minute occlusion was lethal in ADK overexpressing animals. 
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ble to tailor adenosine receptor modulating drugs to patients 
based on the area of ischemia as more is learned about the 
location specific properties of adenosine receptors. Perhaps 
A2A  receptor  antagonism  would  be  a  more  potent  therapy 
than for patients with striatal strokes than those with primar-
ily cortical injury. 
  Surprisingly, peripheral stimulation of A2A receptors has 
also been shown to provide protection to cerebral ischemia in 
vivo [98, 108]. Systemic administration of A2A receptor ago-
nists protect against spinal  chord ischemia-reperfusion and 
traumatic spinal chord injury in vivo [17, 89]. Direct admini-
stration  of  A2A  receptor  agonists  to  the  brain  immediately 
preceding intracerebral hemorrhage reduce cell death [68]. In 
these cases, protection afforded by A2A receptor agonists is 
attributed  to  a  reduction  of  neutrophil  infiltration  into  the 
affected tissue. Stimulation of A2A receptors has been shown 
to decrease production of proinflammatory cytokines by pe-
ripheral  immune  cells  [14,  64],  which  may  play  a  role  in 
exacerbating injury in the CNS. However, elucidation of the 
distinct contributions of A2A receptors in the CNS and in the 
periphery to ischemic damage has proven difficult.  
  A2AR  knockout  bone  marrow  chimera  mice  have  been 
created to separately address the peripheral and CNS effects 
of A2A receptors. As stated previously, A2AR knockout mice 
are protected from cerebral ischemic damage [20]. Similarly, 
A2AR knockout mice are protected from compression injury 
of  the  spinal  chord  when  compared  to  wild-type  controls 
[63]. Chimeric mice lacking A2A receptors in non Bone Mar-
row  Derived  Cells  (BMDCs)  also  show  protection  from 
compression, but only a small reduction in damage due to 
infarct is seen in these mice. Notably, protection in spinal 
compression injury is abolished in wild-type/knockout bone 
marrow chimera mice that lack the A2A receptor in BMDCs 
but is retained in cerebral  ischemia [20, 63]. Interestingly, 
the  amelioration  of  damage  in  chimeric  mice  lacking  A2A 
receptors  on  BMDCs  is  not  as  robust  as  in  global  A2A 
knockout animals. These results suggest that neuroprotection 
in these two models of injury may be mediated differentially. 
In the case of ischemic injury, over 90% of the microglia in 
the damaged area of chimeric mice were found to be brain 
derived, indicating that suppression of inflammation in pe-
ripheral  BMDCs  may  not  have  been  significant  in  this 
circumstance [20]. A2A receptor activation may be beneficial 
acutely in the periphery by acting on brain endothelium to 
increase cerebral blood flow and by reducing inflammatory 
cytokine  production  by  immune  cells,  while  A2A  receptor 
antagonism may be beneficial in the CNS during later stages 
of ischemia, when prolonged activation of neurons could be 
detrimental. For a more thorough discussion of A2A recep-
tors as a target for neuroprotection, please see Roderigo et 
al.,  this  issue.  Additionally,  A2A  receptor  pharmacology  is 
discussed in more detail in the review by Shen et al., also in 
this issue. 
A2B Receptor Effects in the CNS 
  The effects of adenosine A2B receptors during ischemia 
are not as well characterized as those of A2A receptors. A2B 
receptors are perhaps the least studied member of the adeno-
sine receptor family. A2B receptors are present on vascular 
smooth muscle and endothelial cells, as well as on astrocytes 
[34, 54]. Due to their low affinity for adenosine, and their 
relative paucity in the brain, A2B receptors seem to be acti-
vated only under hypoxic or ischemic conditions, when lev-
els of adenosine surge [59, 92]. Recent in vitro studies have 
suggested a role for A2B receptors in production of glial cell 
line-derivate  neurotrophic  factor  (GDNF)  by  astrocytes 
[114].  Adenovirus-mediated  GDNF  pretreatment  has  been 
shown to reduce cell death following Middle Cerebral Artery 
Occlusion (MCAO) by both intracerebral and systemic ad-
ministration [48, 58]. Intracerebral infusion of GDNF post-
MCAO  increases  striatal  neurogenesis  in  rat,  indicating  a 
possible role in regeneration as well as protection [60]. A2B 
receptors  may  also  regulate  vascular  leak  during  hypoxia 
[30], potentially contributing to increased blood flow to af-
fect tissues. Studies of si-RNA mediated A2B receptor sup-
pression in vitro have shown increased endothelial leak in 
response  to  hypoxia,  and  A2B  receptor  knockout  animals 
show increased vascular permeability as compared to wild-
type or other adenosine receptor knockout animals [30]. The 
ablation of the A2B receptor in mice leads to a basal level of 
low-grade inflammation and increased leukocyte adhesion to 
the vasculature [115]. A2B receptor mice also display an en-
hance  expression  of  pro-inflammatory  cytokines  as  com-
pared to control mice. Bone marrow transplantation studies 
indicate that these processes are regulated primarily by bone 
marrow, and to a lesser extent vascular, A2B receptors [115]. 
Taken  together,  these  results  indicated  that  A2B  receptors 
might  afford  protection  to  the  CNS  when  activated  under 
ischemic conditions, either directly or by decreasing inflam-
mation and reducing immune cell adhesion to vascular endo-
thelium.  
A3 Receptor Effects in the CNS 
  A3 receptors stimulate inhibitory G proteins. Like A1 re-
ceptors, A3 receptor activation inhibits adenylyl cyclase and 
leads  to  the  activation  of  phospholipase  C.  However,  the 
affinity  of  A3  receptors  for  adenosine  is  the  lowest  of  all 
subgroups, on the order of 6500 nM, which is roughly 100 
times lower than the affinity of A1 receptors [29]. A3 recep-
tors are found throughout the brain, though they are present 
at levels 10-30 fold lower than A1 or A2 receptors [107]. In-
terestingly, A3 receptors on CNS cells have been shown to be 
involved in both cell survival and death, depending on the 
degree  of  receptor  activation  and  the  specific  pathophysi-
ological conditions [1]. More specifically, long duration ac-
tivation of A3 receptors leads to cell death via necrosis or 
apoptosis, while short-term stimulation of central A3 recep-
tors prior to injury may reduce spontaneous apoptosis [109]. 
Application of A3 receptor antagonists to hippocampal slices 
during  prolonged  oxygen-glucose  deprivation  (OGD)  pre-
vents neuronal loss in the CA1 region [87]. Interesting, dur-
ing brief periods of OGD, A3 receptors antagonism resulted 
in faster recovery of fEPSP, indicating an inhibitory role of 
these  receptors  during  initial  hypoxia  [87].  Chronic  pre-
exposure to A3 agonist is protective in vivo; this may be due 
to rapid desensitization of A3 receptors [80, 106]. Intrave-
nous or ICV administration of the selective A3 receptor ago-
nist Cl-IB-MECA 165 minutes and 15 minutes prior to the 
onset of transient ischemia is protective in rats [18]. Consis-
tent with these results, A3 knockout animals have increased 
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ischemic administration of Cl-IB-MECA is also protective in 
vivo [110]. Interestingly, in contrast to in vitro results, a sin-
gle dose of Cl-IB-MECA given acutely during focal ische-
mia  increased  infarct  volume  [109].  These  results  suggest 
that the effects of A3 receptor signaling during ischemic in-
jury may be beneficial or detrimental depending on the spe-
cific circumstances in which the stimulus occurs. Correctly 
timed, A3 receptor modulation may be a potential target for 
therapeutic  intervention.  Early  chronic  stimulation  of  A3 
receptors leading to their down regulation, or acute A3 recep-
tor blockade, may be one strategy for inducing prophylactic 
neuroprotection in advance of predicted ischemic injury.  
PAST COMPLICATIONS IN DEVELOPING ADENO-
SINE-BASED THERAPIES FOR STROKE 
  A major stumbling block in the development of adeno-
sine-based neuroprotective strategies has been the dramatic 
systemic effects of adenosine which include decreased heart 
rate, blood pressure and body temperature, and sedation [9]. 
As more specific adenosine receptor agonists and antagonists 
are  developed,  drugs  with  fewer  off-target  effects  may 
emerge. Novel therapeutic methods may also allow for easier 
local delivery of adenosine, or modulators of specific adeno-
sine receptors, to the central nervous system. A novel exam-
ple  of  one  such  strategy,  the  implantation  of  adenosine-
releasing  silk  polymer  to  treat  epilepsy,  can  be  found  in  
Wilz, A. et al., 2008 [112]. Additionally, the systemic effects 
of adenosine may be harnessed to ameliorate damage caused 
by ischemic stroke.  
PERIPHERAL  IMMUNE  INVOLVEMENT  AND  IN-
FLAMMATORY CYTOKINES IN STROKE 
  In  the  context  of  a  pathogen  invasion,  a  vigorous  in-
flammatory response is an effective means to clear an inva-
sive microorganism. Responding immune cells kills not only 
pathogens, but also the cells harboring them. However, when 
this same response is co-opted by the host to clear infarcted 
tissue, it can damage the very cells it is intending to save. 
Much of the damage associated with brain ischemia is due to 
the resultant inflammatory response. This has been demon-
strated by the amelioration of ischemic damage through the 
use of anti-inflammatory strategies [42, 90, 99]. Inflamma-
tion  following  stroke  originates  with  microglia  and  astro-
cytes, which detect injury-associated molecules and produce 
pro-inflammatory cytokines [31, 46]. Vascular endothelium 
becomes activated, signaling to the periphery and increasing 
blood  brain  barrier  permeability  [2,  6].  The  inflammatory 
response  is  further  promoted  by  the  infiltration  of  macro-
phages and neutrophils (Fig. 1). These cells produce prote-
olytic enzymes, inflammatory cytokines and other cytotoxic 
molecules. 
  Proinflammatory cytokines have been implicated in ex-
acerbating the damage in stroke by increasing neuroinflam-
mation, with particular attention paid to TNF-α [5]. TNF-α 
is pleiotropic inflammatory cytokine that is produced by a 
variety of cell types, including peripheral immune cells and 
cells that are resident in the CNS. Intravenous administration 
of anti-TNF-α antibody to mice following transient cerebral 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Peripheral immune involvement following ischemic brain injury. Neurons and astrocytes damaged by ischemia release pro-
inflammatory factors such as TNF-α into the brain parenchyma. These pro-inflammatory molecules in turn diffuse and bind receptors on 
vascular endothelial cells. Activation of endothelial cells via TNF and related receptors leads to nuclear factor kappa B (NFκB) activation 
and nuclear translocation. In the nucleus, NFκB activity induces transcription of adhesion molecules and chemokines, including E-selectin, 
P-selectin, vascular cell adhesion molecule (VCAM1), intercellular adhesion molecule (ICAM1) and heparin sulfate proteoglycan. Peripheral 
immune  cells  traveling  through  the  vasculature  express  receptors  to  adhesion  molecules  (i.e.  PSGL-1  for  selectins,  α4-βintegrin  for 
VCAM1). As they survey the body, leukocytes roll along the activated endothelium, adhere via adhesion molecules and become activated 
themselves, then extravasate into the brain parenchyma. 222    Current Neuropharmacology, 2009, Vol. 7, No. 3  Williams-Karnesky and Stenzel-Poore 
ischemia has been shown to ameliorate damage and reduce 
edema [51]. Adenosine receptor agonists and antagonists are 
both effective suppressors of TNF-α through their actions on 
various  cell  types.  In  rabbits  undergoing  transient  spinal 
chord  ischemia,  lower  levels  of  plasma  TNF-α  and  de-
creased damage are seen following intravenous administra-
tion  of  the  adenosine  A2A  analogue  ATL-146e  (4-(3-[6-
amino-9-(5-ethylcarbamoyl-3,4-dihydroxy-tetrahydro-furan-
2-yl)-9H-purin-2-yl]-prop-2-ynyl)-cyclohexanecarboxylic  acid 
methyl ester) [16]. Understanding how adenosine modulates 
the release of TNF-α by both peripheral immune cells and by 
cells in the CNS may be particularly beneficial when devel-
oping adenosine based therapies for the treatment of stroke. 
The effects of TNF-α on adenosine receptor expression may 
also provide insight into the phenomenon of ischemic pre-
conditioning, a phenomenon in which a brief noxious stimuli 
induce changes in the CNS and in the periphery that result in 
endogenous neuroprotection from stroke. 
THE  EFFECTS  OF  ADENOSINE  ON  THE  PERIPH-
ERAL IMMUNE SYSTEM 
  Adenosine may play a role in modulating systemic im-
mune involvement in stroke that is in addition to its role in 
the  CNS.  Adenosine  levels  in  serum  increase  following 
stroke  [62].  This  finding  is  particularly  significant,  as  pe-
ripheral  immune  cells  express  functional  adenosine  recep-
tors, and respond to changes in extracellular adenosine (Fig. 
2). It is also important to consider the peripheral effects of 
adenosine-based therapeutics, as systemic administration of 
adenosine-modulating drugs affect immune cells as well as 
the CNS. 
Effects of Adenosine on Monocytes and Macrophages 
  Monocytes  and  macrophages  express  the  full  comple-
ment  of  A1,  A2A,  A2B,  and  A3  receptors.  Stimulation  via 
adenosine  receptors  not  only  shapes  macrophage  function, 
but  can  also  influence  differentiation.  High  levels  of  ex-
tracellular  adenosine  can  delay  monocyte  maturation  [35]. 
Broadly, extracellular adenosine has the affect of changing 
the response of macrophages from proinflammatory to anti-
inflammatory. Adenosine inhibits TNF-α and IL-12 produc-
tion,  while  increasing  IL-10  production  by  macrophages 
[44]. These effects appear to be primarily mediated via A2A, 
A2B and A3 receptors [43]. Recent results have shown that 
A2B receptor activation with the selective agonist BAY 60-
6583 on macrophages in vitro and in vivo leads to decreased 
production of TNF-α following injurious stimuli [19]. How-
ever, it should be noted that adenosine has differential effects 
on  macrophage  development  depending  on  the  receptor  it 
stimulates. Stimulation via A 1 receptors has been found to 
influence  monocytes  to  become  phagocytic  multinuclear 
giant cells, while stimulation via A2A and A2B receptors has 
been shown to inhibit this process [71]. Monocytes also af-
fect resolution of ischemic damage by influencing vasacular 
endothelial  cells.  Application  of  the  selective  A1  receptor 
agonist  CPA  (N
6-cyclopentyladenosine)  to  macrophages 
results  in  increased  production  of  vascular  endothelial 
growth  factor  (VEGF),  leading  to  an  increase  in  capillary 
formation  in  vitro  [22].  When  activated,  macrophages  can 
themselves be a source of extracellular adenosine, via ATP 
production [44]. Through this local extracellular production 
of adenosine, macrophages may also suppress the inflamma-
tory response of other immune cells. Monocytes and macro-
phages exert broad influence on damage and healing follow-
ing stroke. Stimulation of the A2A receptor inhibits produc-
tion  of  TNF-α,  decreasing  inflammation  at  the  time  of 
ischemia. Therapies that increase the expression of A2A re-
ceptors,  such  as  the  Toll-like  receptor  4  (TLR4)  agonist 
lipopolysaccharide (LPS) [102], may be useful as a prophy-
lactic to modulate the response of macrophages to endoge-
nous adenosine release during ischemic injury.  
Effects of Adenosine on T and B Lymphocytes 
  Recruitment of activated lymphocytes to the brain paren-
chyma  following  stroke  leads  to  increased  tissue  damage 
[52]. Adenosine may serve as a negative regulator of lym-
phocyte activation, and thereby reduce damage caused by an 
excessive inflammatory response. Lymphocytes express A2A, 
A2B and A3 adenosine receptor subtypes [39]. Similar to what 
is seen in macrophages, stimulation of adenosine receptors 
on lymphocytes has the net effect of suppressing activation. 
The adenosine A2A receptor has been directly implicated in 
adenosine-mediated suppression of cytokine production and 
cytotoxic activity in natural killer T cells, a highly special-
ized group of T lymphocytes [50]. Additionally, evidence is 
mounting to support the hypothesis that adenosine mediates 
the formation of T regulatory cells [43, 118]. Unlike cyto-
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Adenosine modulates peripheral immune cell function. 
Adenosine modulates the activity of peripheral immune cells differ-
entially depending on the receptors that are activated. Overall, acti-
vation of A2A  and A2B receptors directs immune  cells to  an  anti-
inflammatory response. This property could be harnessed in stroke 
to reduce inflammatory damage in the CNS caused by infiltrating 
activated  immune  cells.  Stimulation  via A 1  receptors  on  immune 
cells tends to increase migration and activity, but also leads to angi-
ogenesis through their interaction with cerebral vascular endothelial 
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toxic T lymphocytes, regulatory T cells serve as suppressors 
of  inflammation,  and  can  limit  damage  to  healthy  tissues 
caused  by  overactivated  immune  cells.  Surprisingly,  the 
regulatory function of T regulatory cells has been linked to 
their ability to produce adenosine [25]. A2A receptors appear 
to be the dominant receptor subtype mediating the immuno-
suppressive effects of adenosine on  lymphocytes. Stimula-
tion of  the A2A receptor in  mixed lymphocyte populations 
leads to a decrease in expression of the intercellular adhesion 
molecule  ICAM,  decreased  production  of  several  proin-
flammatory  cytokines,  and  decreased  proliferation  [103]. 
However, it should be noted that the actions of A2A receptor 
stimulation could be blocked via A1 or A3 receptor activation 
[103]. While this may be relevant with acute systemic ad-
ministration of adenosine-based therapeutics selective for A1 
and A3 agonists, the negative consequences could potentially 
be overcome by using short-acting, CNS-targeted drugs.  
Effects of Adenosine on Neutrophils and other Granulo-
cytes  
  Neutrophils are granulocytes, members of the polymor-
phonuclear family of cells, which also includes eosinophils 
and  basophils.  Following  activation  by  cytokines  and 
chemokines,  neutrophils  upregulate  intracellular  adhesion 
molecules, adhere to vascular endothelium and migrate into 
damaged tissue. Migration of neutrophils occurs well before 
migration of monocytes or lymphocytes [113]. Once at the 
site of inflammation, neutrophils release preformed granule 
constituents,  lytic  enzymes,  reactive  oxygen  species,  and 
inflammatory cytokines such as TNF-α [47]. While helpful 
in the context of response to infection with a pathogen, as 
with  other  immune  cells,  over-activation  of  neutrophils  at 
sites of injury can exacerbate damage by damaging healthy 
tissue.  Neutrophils  in  particular  are  strongly  recruited  fol-
lowing ischemic-reperfusion injury, and have been shown to 
contribute  significantly  to  subsequent  neuroinflammatory 
damage [111]. It has long been known that adenosine pro-
motes migration of neutrophils, and it has recently come to 
light that this occurs via stimulation of A1 and A3 receptors 
[21, 95]. Conversely, by acting via A2A receptors, adenosine 
down  regulates  surface  expression  of  adhesion  molecules, 
and decreases the production of pro-inflammatory cytokines 
[43].  Application  of  the  adenosine  kinase  inhibitor  GP515 
attenuates neutrophil degranulation via an adenosine-mediated 
action [12]. This action appears to be mediated strongly by 
A3 receptors, as well as by A2A receptors, but not by A1 re-
ceptors  [12].  In  mast  cells,  A2A  receptor  stimulation  also 
bocks  degranulation,  while  A2B  receptor  activation  causes 
release of VEGF [22]. Taken together, these results indicate 
that A2A receptors serve as a negative regulator of granulo-
cyte-induced inflammation, while A1 receptors may promote 
the inflammatory properties of these cells. A3 receptors ap-
pear to have mixed effects on neutrophils, depending on the 
context in which the stimulation occurs.  
  Neutrophils infiltrate into the brain parenchyma follow-
ing  ischemic  injury,  contributing  to  immune  mediated  in-
flammatory  damage  following  stroke;  adenosine  receptors 
provide an accessible, potential target for modulation of the 
proinflammatory properties of these cells. Overall, A2A re-
ceptor  stimulation  on  neutrophils  acutely  and  immediately 
following  stroke  likely  decreases  inflammatory  damage. 
Compounds that directly induce expression of A2A receptors 
on neutrophils such as LPS, or those that elicit the release of 
cytokines like TNF-α, Interleukin 1β (IL-1β) [36], may be 
useful  as  prophylactic  neuroprotectants  by  reprogramming 
the response of neutrophils to stroke. 
A PUTATIVE ROLE FOR ADENOSINE IN PROPHY-
LACTIC NEUROPROTECTION 
  It is well known that  certain antecedent treatments  can 
protect  patients  from  damage  due  to  an  ischemic  episode. 
Cerebral ischemic preconditioning has emerged as a promis-
ing field of study for the development of prophylactic neuro-
protectants. Ischemic preconditioning can be induced by  a 
variety  of  noxious  stimuli,  including  short  periods  of  hy-
poxia or ischemia, cortical spreading depression, brief sei-
zure, exposure to inhaled anesthetic or low dose of bacterial 
endotoxin [27]. Preconditioning that occurs rapidly, immedi-
ately following stimulation, is termed acute preconditioning. 
Local increase of adenosine in the brain is likely one of the 
mechanisms  by  which  acute  preconditioning  occurs  [24]. 
Rapid  upregulation  of  neuroprotective  A1  receptors  in  the 
brain has been shown to be one mechanism of adenosine-
mediated acute preconditioning. When given during a brief 
conditioning  period  of  ischemia,  the  selective  A1  receptor 
agonist  DPCPX  attenuates  the  protective  effects  of  acute 
preconditioning [3, 75]. Rapid tolerance against focal ische-
mia by isoflourane is also attenuated by DPCPX administra-
tion [65]. As an additional mechanism, rapid adenosine re-
ceptor desensitization may contribute to acute neuroprotec-
tive as is seen following chronic A3 receptor agonism [80].  
  Neuroprotection  that  develops  over  a  period  of  several 
hours or days and requires new protein synthesis is termed 
delayed preconditioning. As in acute preconditioning, adeno-
sine  may  play  a  role  in  delayed  preconditioning.  ATP 
diphosphohydrolase  and  5’-nucleotidase,  two  enzymes  in-
volved in the local production of adenosine from ATP via 
hydrolysis, show enhanced activity in the CA1 region of the 
hippocampus following brief ischemia. This increase in en-
zymatic activity correlates with protection in the CA1 region 
from  subsequent  ischemic  injury,  given  48  hours  later. 
Adenosine  receptor  blockade  blocks  tolerance  to  ischemia 
induced by preconditioning. As with acute preconditioning, 
the neuroprotective effects of ischemic preconditioning are 
attenuated with the administration of the selective A1 agonist 
DPCPX at the time of conditioning ischemia [49, 116]. In-
terestingly, DPCPX administered at the time of ischemia, 72 
hours after preconditioning, does not reverse protection, im-
plying a role for A1 receptors during conditioning ischemia 
[116].  
  Unmethylated  cytosine-guanine  rich  oligodinucleutides 
(CpG  ODNs),  which  act  on  Toll-like  receptor  9  (TLR9), 
have been shown to be a highly effective means of prophy-
lactic neuroprotection in a mouse model of cerebral ischemia 
[101]. The delayed neuroprotection afforded by CpG ODNs 
occurs following systemic injection. CpG ODNs also confer 
protection from oxygen-glucose deprivation in mixed corti-
cal cultures in vitro. Similar finding have been previously 
reported for the TLR4 agonist LPS [96]. An increase in sys-
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LPS- and CpG-mediated preconditioning [96, 101]. Interest-
ingly,  proinflammatory  cytokines  such  as  TNF-α  increase 
the expression and signaling of A1 receptors in the brain [7]. 
Upregulation of A1 receptors in the CNS, effectively prepar-
ing the brain for ischemic insult, may be one mechanism by 
which  TLR  agonists  elicit  endogenous  neuroprotection. 
TNF-α also upregulates A2A and A2B receptor expression on 
endothelial  cells,  which  may  contribute  to  suppression  of 
inflammation following ischemic injury [73, 100]. This con-
tribution may be highly relevant, as stimulation of these re-
ceptors on vascular endothelial cells suppresses expression 
of adhesion molecules such as E-selectin and vascular cell 
adhesion  molecule  (VCAM-1)  [13].  Stimulation  of  excita-
tory A2A receptors enhances nitric oxide release and vasodi-
lation [86], and stimulation of A2B receptors leads to expres-
sion  of  angiogenic  factors  [33].  TNF-α  also  leads  to  the 
upregulation  of  A2A  receptors  on  peripheral  immune  cells 
[56]. Upregulation of A2A receptors on neutrophils  is seen 
following  stimulation  with  TNF-α,  which  may  reduce  the 
damage caused by inflammatory immune infiltrate into the 
brain  following  stroke  [36].  With  these  specific  adenosine 
receptors  increased,  immune  cells  may  be  more  likely  to 
produce  an  anti-inflammatory  response  in  the  setting  of 
stroke especially when in conjuction with increased produc-
tion of adenosine. In support of this idea, A2A receptors have 
been  shown  to  decrease  TNF-α  production  and  adhesion 
molecule expression following stimulation with TLR4 ago-
nists [41], which are also released endogenously following 
stroke [67]. Indeed, synergism between adenosine and TLRs 
are well documented, especially in peripheral immune cells 
[66, 77, 88]. While the involvement of adenosine receptors 
in  TLR-mediated  preconditioning  has  not  been  confirmed, 
direct regulation of adenosine-related gene products is also 
seen via microarray analysis in both brain and blood follow-
ing  TLR-mediated  preconditioning  (Stenzel-Poore  lab,  un-
published observation). For a more extensive discussion of 
TLR  signaling  in  endogenous  neuroprotection  and  stroke, 
please see the 2009 review by Marsh, B. J. et al. [67]. A 
greater understanding of the role of adenosine in endogenous 
neuroprotection  may  lead  to  interventions  and  therapeutic 
strategies useful in ischemia. A focus on the interaction be-
tween TLRs and adenosine receptors in preconditioning may 
be appropriate because systemic TNF-α levels may remain 
lower—a feature  that  is preferable in the  treatment of pa-
tients. 
CONCLUSION AND PERSPECTIVE 
  Stroke is a leading cause of death and disability in the 
United States [74]. Despite years of study, there is only one 
clinical  therapy  for  the  treatment  of  stroke--removal  of 
thrombus mechanically or via lysis by administration of tis-
sue plasminogen activator (tPA) [79]—and tPA is, at best, an 
imperfect treatment. Thrombolysis is only applicable in the 
setting of occlusive stroke, treatment must be applied within 
a short time window, and the risk for hemorrhagic episodes 
following  tPA  are  high  [26].  Though  no  adenosine-based 
therapies  for  treatment  of  stroke  exist,  selective  activation 
and inhibition of adenosine receptors in the CNS, especially 
when  combined  with  peripheral  immune  modulation,  is  a 
promising target for future stroke therapies. Perhaps the most 
benefit will be gained through the use of prophylactic thera-
pies that alter the expression of adenosine receptors on spe-
cific  cells  types.  Utilization  of  complementary  molecules, 
such as prophylactic TLR-agonists, will also improve stroke 
treatment  by  enhancing  the  benefits  of  adenosine  receptor 
stimulation.  The future success of stroke  therapy does not 
rest on the discovery of a novel miracle compound, but on 
the intelligent design of multimodal, synergistic treatments 
that target several sources of damage.  
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